Pages that link to "Q35536768"

The following pages link to Angiogenic cytokines in patients with idiopathic interstitial pneumonia (Q35536768):

Displaying 37 items.

• Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis (Q26750418) (← links)
• A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis (Q28383207) (← links)
• Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. (Q30398970) (← links)
• Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis (Q33732623) (← links)
• Mediators leading to fibrosis - how to measure and control them in tissue engineering. (Q34159587) (← links)
• Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? (Q34882979) (← links)
• Angiogenic Activity of Sera from Pulmonary Tuberculosis Patients in Relation to IL-12p40 and TNFα Serum Levels (Q35120028) (← links)
• Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function (Q35179145) (← links)
• Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis (Q35558781) (← links)
• Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice (Q35855163) (← links)
• Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells (Q36303468) (← links)
• Pulmonary hypertension in parenchymal lung disease (Q36328903) (← links)
• Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis. (Q36390205) (← links)
• Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy (Q36440438) (← links)
• Angiogenic activity of sera from interstitial lung disease patients in relation to clinical and radiological changes (Q36464112) (← links)
• Clinical implications for vascular endothelial growth factor in the lung: friend or foe? (Q36625050) (← links)
• Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots (Q36719113) (← links)
• The inter-connection between fibrosis and microvascular remodeling in idiopathic pulmonary fibrosis: Reality or just a phenomenon. (Q36766700) (← links)
• Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury. (Q36960794) (← links)
• VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats (Q37170742) (← links)
• Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion (Q37313133) (← links)
• The pathogenesis of idiopathic pulmonary fibrosis. (Q37800756) (← links)
• Towards a better diagnosis of idiopathic pulmonary fibrosis (Q37883793) (← links)
• Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. (Q37937430) (← links)
• Physiological and pathological angiogenesis in the adult pulmonary circulation (Q38111715) (← links)
• Molecular biomarkers in interstitial lung diseases. (Q38220769) (← links)
• Management of Pulmonary Hypertension in Patients with Chronic Lung Disease (Q38538687) (← links)
• Pulmonary hypertension associated with lung diseases and hypoxemia (Q38810145) (← links)
• Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. (Q38981777) (← links)
• Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis (Q39401141) (← links)
• Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. (Q41703248) (← links)
• Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis (Q43196827) (← links)
• Relationship between quantitative CT metrics and pulmonary function in combined pulmonary fibrosis and emphysema (Q51226432) (← links)
• VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. (Q52309706) (← links)
• Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer (Q64083648) (← links)
• Angiogenic activity of sera from extrinsic allergic alveolitis patients in relation to clinical, radiological, and functional pulmonary changes (Q84533965) (← links)
• Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer (Q87193514) (← links)